10x Genomics (TXG) Q2 2025: Spatial Consumables Up 24% as Single-Cell Volumes Outpace Pricing Headwinds
Spatial consumables growth and single-cell reaction volumes both outperformed in a persistently constrained funding environment. Despite academic and capital spending headwinds, TXG’s core consumables demand indicators remained robust, with spatial platforms and new product launches driving adoption. Strategic acquisition of Scale Biosciences and disciplined cost management position TXG for long-term innovation, though near-term visibility remains clouded by funding uncertainty and pricing transitions.
Summary
- Spatial Demand Resilience: Spatial consumables outpaced expectations, led by Xenium adoption and increased per-run spend.
- Single-Cell Volume Elasticity: Chromium reaction volumes grew despite lower average prices, reflecting underlying demand strength.
- Strategic Portfolio Expansion: Scale Biosciences acquisition targets broader access and future cost leadership in single-cell analysis.
Performance Analysis
10x Genomics navigated a persistently challenging macro environment in Q2, with global academic funding delays and capital equipment constraints weighing on top-line results. Excluding a one-time $68 million litigation settlement, core revenue declined 5% year over year as instrument sales remained pressured, particularly in the Americas and EMEA. Consumables, the company’s recurring revenue engine, demonstrated resilience: Spatial consumables revenue rose 24% year over year, driven by strong Xenium platform utilization and increased spend per run, while Chromium consumables revenue declined 9% as lower prices offset higher reaction volumes.
Instrument sales were especially weak, with spatial instruments down 42% and Chromium instruments down 35% as customers deferred capital purchases and TXG implemented strategic discounts to drive placements. Service revenue, up 47%, reflected expanding Xenium service plans. By geography, APAC (Asia-Pacific) stood out, up 41% year over year, aided by a $4 million tariff-driven pull-forward in China, while Americas and EMEA remained soft. Gross margin improved to 72% on settlement revenue, but underlying margins and operating loss (excluding settlement) reflected ongoing price and cost pressure. Cash generation and a $447 million balance sheet provide flexibility as TXG invests in innovation and cost discipline.
- Spatial Consumables Momentum: Xenium platform drove both volume and revenue growth, with broadening adoption and higher per-run spend.
- Single-Cell Reaction Growth: Chromium reaction volumes increased year over year and sequentially, even as average prices fell.
- Instrument Discounting: Strategic price reductions drove 11% more Chromium placements but diluted average selling prices.
Overall, TXG’s consumable-driven model showed elasticity and resilience, but capital sales and pricing transitions remain near-term headwinds. The company’s focus on cost control and innovation supports long-term positioning despite current uncertainty.
Executive Commentary
"We continue to see solid signs of underlying single-cell demand. On the consumable side, while revenue was down year over year, chromium reaction volumes grew both year over year and sequentially, an indicator of increasing demand for our solutions and single-cell more broadly."
Serge Saxonoff, CEO and Co-Founder
"We implemented strategic discounts during the quarter as we partnered with customers who were navigating capex constraints. These discounts drove broader instrument adoption and an 11% increase in chromium placements year over year."
Adam Teich, Chief Financial Officer
Strategic Positioning
1. Consumables-Centric Growth Model
TXG’s business model is anchored in recurring consumables revenue, which provides more stability than capital equipment sales in volatile funding cycles. Spatial and single-cell consumables remain the company’s primary growth engines, with new product launches (like GEMEX, Flex, and Universal On-Chip Multiplex) lowering cost barriers and expanding use cases. The company’s focus on increasing reaction volumes, rather than just price, underpins its long-term strategy for market expansion.
2. Product Innovation and Roadmap Execution
Recent and upcoming product launches are central to TXG’s differentiation, with Vizium HD 3 Prime and HD cell segmentation expanding spatial analysis capabilities. Flex V2, a next-generation plate-based single-cell product, is designed to boost throughput and enable large-scale perturbation studies, critical for AI-driven biology. The roadmap also includes multi-omics capabilities and protein-RNA analysis, reinforcing TXG’s leadership in high-value applications.
3. Strategic M&A: Scale Biosciences Acquisition
The acquisition of Scale Biosciences is a targeted technology play, giving TXG access to combinatorial indexing and quantum barcoding IP. This move aims to lower the cost per cell and broaden access to single-cell analysis, positioning TXG for future growth as large-scale studies and AI applications become more prevalent. Management emphasized integration with existing workflows and minimal near-term revenue impact, but sees long-term strategic value in expanding the addressable market.
4. Geographic Diversification and Channel Adaptation
APAC, and specifically China, emerged as a bright spot, with local market adaptations and a revamped go-to-market model driving improved execution and visibility. While the $4 million tariff-driven pull-forward is a one-off, underlying demand trends are favorable, reflecting successful channel investments and closer customer engagement.
5. Cost Management and Operational Discipline
TXG remains focused on cost efficiency and cash generation, with recent headcount reductions, commercial restructuring, and disciplined OpEx control. The company’s strong balance sheet and cash position provide a buffer against ongoing funding uncertainty and enable continued investment in R&D and M&A.
Key Considerations
This quarter reinforced the duality of TXG’s business: robust consumables demand and innovation offset by persistent funding and price headwinds. Investors should focus on the interplay between volume growth, pricing transitions, and the pace of new product adoption.
Key Considerations:
- Funding Volatility Persists: Academic and government funding uncertainty continues to delay project starts and capex purchases, especially in the US and EMEA.
- Elasticity in Consumables Demand: Higher single-cell reaction volumes and spatial consumables growth highlight the market’s sensitivity to lower prices and new applications.
- Strategic Discounting as Market Entry Lever: Instrument price reductions are driving broader placement but at the cost of near-term margins.
- Scale Acquisition Expands TAM: Integrating Scale’s technology could accelerate TXG’s push into lower-cost, higher-scale single-cell analysis, positioning for the AI-driven biology wave.
- Operational Execution in China: Localized strategies and improved customer proximity are yielding sustained growth, even as short-term tariff effects fade.
Risks
Persistent funding uncertainty, especially in US academic markets, continues to cloud near-term visibility and delay capital purchases. Pricing transitions and increased discounting could pressure margins if volume growth does not fully offset lower ASPs (average selling prices). Integration risk exists with the Scale Biosciences acquisition, though management downplays near-term financial impact. Macro and regulatory volatility, especially around tariffs and grant disbursements, remain material headwinds.
Forward Outlook
For Q3 2025, TXG guided to:
- Revenue of $140 million to $144 million, reflecting a $4 million pull-forward in Q2 from China.
For full-year 2025, management maintained a cautious stance:
- Revenue expectations to remain flat sequentially, with ongoing capex and funding constraints limiting upside.
Management highlighted several factors that will shape the second half:
- Spatial consumables and single-cell reaction volumes expected to remain robust.
- Capital equipment sales to remain pressured until funding visibility improves.
Takeaways
TXG’s core consumables business is proving resilient, with spatial and single-cell volumes outpacing pricing headwinds. Strategic innovation and disciplined cost management provide a foundation for long-term growth, but investors should remain cautious on near-term revenue and margin trajectory given the external funding environment.
- Consumables Strength: Spatial and single-cell consumables are driving recurring revenue, with new products expanding addressable applications.
- Margin and Pricing Dynamics: Discounting and lower ASPs are near-term headwinds, but volume elasticity and cost control are mitigating factors.
- Future Watchpoint: Funding clarity, grant disbursements, and the integration of Scale technology will be critical to monitor in the coming quarters.
Conclusion
10x Genomics demonstrated underlying demand resilience in its consumables business, even as funding headwinds and pricing transitions weighed on reported growth. The company’s strategic focus on innovation, cost discipline, and portfolio expansion positions it for long-term leadership, though near-term volatility in academic and capital spending will continue to pose challenges.
Industry Read-Through
TXG’s results highlight the ongoing bifurcation in life science tools: recurring consumables revenue remains relatively robust, while capital equipment sales are acutely sensitive to funding cycles and macro uncertainty. Spatial biology and single-cell analysis are proving to be high-growth subsectors, with increasing adoption driven by AI and large-scale translational studies. Instrument discounting and pricing transitions are likely to persist across the industry as vendors seek to broaden installed base and capture downstream consumables growth. Strategic M&A for technology access and cost leadership is set to accelerate as the competitive landscape shifts toward scale and integration, with implications for both incumbents and emerging players.